The OncoMelanoma Panel is designed to detect mutations within oncogenes frequently mutated in human melanomas. Diagnostic, prognostic, and predictive biologic markers in this panel are important in personalizing cancer care. The result of this test may guide a patient to the appropriate chemotherapy or clinical trial. The OncoMelanoma Panel is designed to target ~425 mutations in the following 8 critical melanoma-related genes: BRAF, CTNNB1, GNA11, GNAQ, KIT, NRAS, KRAS and HRAS. 1,2,3,4,5
To open a printable assay summary in a new window, click the link below.
(Targeted analysis for ~425 hotspot mutations within genes mutated in melanomas (BRAF, CTNNB1, GNA11, GNAQ, KIT, NRAS, KRAS, HRAS))
- Rothberg JM, et al; An integrated semiconducted device enabling non-optical genome sequencing. Nature, 2011 Jul20; 475(7356):348-52
- Dancey JE, et al; The genetic basis for cancer treatment decisions. Cell, 2012 Feb 3; 148(3): 409-20. Review